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We used quantitative real-time reverse transcription–
PCR to measure viral load in serum from 24 patients in 
Kosovo who had acute Crimean-Congo hemorrhagic fever. 
Viral load correlated with clinical disease and antibodies 
and could be used as a predictor of disease outcome.
C
rimean-Congo hemorrhagic fever (CCHF), caused by 
CCHF virus, is a potentially fatal infection in Africa, 
Asia, Eastern Europe, and the Middle East. CCHF virus 
is transmitted to humans by bites of Ixodid ticks and from 
person to person by contact with blood or blood-containing 
body ﬂ  uids. Therefore, nosocomial and intrafamiliar cas-
es are frequently reported in CCHF outbreaks (1). CCHF 
can be treated with ribavirin, but the decision about which 
CCHF patients should be given the drug may be difﬁ  cult 
(2,3). Classiﬁ  cation of patients according to criteria of dis-
ease severity is an important step in deciding whether to 
initiate antiviral therapy and is based on clinical data and 
biochemical test results (2,4). Because of severe side ef-
fects from ribavirin treatment, early laboratory conﬁ  rma-
tion would be desirable to establish stronger criteria for 
case classiﬁ  cation of CCHF.
Real-time PCR has enabled measurement of viral 
loads, monitoring of antiviral treatment effects and emer-
gence of antiviral resistant strains, and prediction of dis-
ease progression and outcome (5). For many viral diseases, 
including hemorrhagic fevers, viral load measurement has 
become an integral part of disease management (6–9). 
However, to our knowledge, the usefulness of viral load 
monitoring for CCHF has never been investigated. Given 
the importance of predicting CCHF disease severity and 
risk for death, our aim was to measure viral load in CCHF 
patients and to correlate it with other laboratory parameters 
and disease outcomes.
The Study
Serum samples were obtained from CCHF patients 
from Kosovo in 2001 (www.who.int/csr/don/2001_06_
29e/en), 2003, and 2005. Clinical and biochemical data 
were provided by the Clinic of Infectious Diseases, Pris-
tina, Kosovo. Presence of an acute febrile syndrome char-
acterized by malaise, nausea, fever, and bleeding from 
various sites was reported as well as possible modes of 
infection. Leukocyte and platelet counts, aspartate and 
alanine aminotransferase levels, activated partial thrombo-
plastin times, and creatinine values were available for most 
patients. Patients were categorized into 3 groups according 
to disease severity: fatal, severe, or moderate cases. On the 
basis of classiﬁ  cation by Swanepoel (4), severe cases were 
deﬁ   ned by the presence of hemorrhagic manifestations 
(epistaxis, hematemesis, and melena), lowered blood pres-
sure (<100/60 mm Hg), and raised serum creatinine and 
transaminase levels.
Serologic testing for anti-CCHF virus immunoglobu-
lin (Ig) M and IgG was done by ELISA. Molecular data 
were obtained by real-time reverse transcription–PCR (RT-
PCR) with a limit of detection of 240 copies/mL of sample 
as recently described (10). Some assay modiﬁ  cations were 
necessary for accurate quantitation of viral load. Synthet-
ic RNA was generated as a quantitative calibrator, and a 
competitive internal control was constructed as previously 
described to detect possible inﬂ  uences of PCR inhibitors 
(11). The original real-time RT-PCR protocol was comple-
mented by the addition of 200 pmol/μL of internal control 
probe YFP2 (5′-ROX-ATCGTTCGTTGAGCGATTAG-
CAG-BBQ-3′). This probe recognizes an alternative bind-
ing site introduced in the target gene by overlap-extension 
PCR (11). The standard curve for CCHF virus quantitation 
was based on synthetic calibrator RNA with concentrations 
from 24 × 105 to 24 × 101 copies/mL. Statistical analysis 
was performed with statistical software R version 2.2.1 
(www.r-project.org) and the Statgraphics 5 package (Ma-
nugistics, Dresden, Germany).
A total of 24 patients had clinical, serologic, and mo-
lecular conﬁ  rmation of CCHF (Table). All 24 patients had 
an acute febrile syndrome, 8 reported tick bites, and 2 had 
been exposed in a hospital. For the 9 patients who died, 
only 1 serum sample was available from each. For the 9 pa-
tients with severe disease and the 6 with moderate disease, 
2–3 consecutive samples were available.
From the 24 patients, 43 serum samples were tested by 
real-time RT-PCR and ELISA (Table). Viral loads ranged 
from 102 to 1010 copies per milliliter of serum, depending 
on the day of illness, the severity of disease, and the results 
of serologic analyses (Table). Whether early laboratory 
ﬁ  ndings could serve as prognostic markers for outcome 
was explored. Because prognostic information is most rel-
evant in the ﬁ  rst week of disease, only samples taken up to 
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day 7 of symptoms from any patient were included in the 
analysis. Average sampling days did not differ between pa-
tients who died and those who survived (5.0 and 3.9 days, 
respectively, p = 0.28, analysis of variance [ANOVA]). No 
patient from either group had detectable IgG in the ﬁ  rst 
week. Although we suspected that early development of 
IgM might correlate with good outcome, such correlation 
was not found. Of those patients in whom IgM was de-
tected up to day 7, 5 (62%) died. Of those without IgM in 
the ﬁ  rst week, 3 (42%) died (insigniﬁ  cant difference in 1-
way ANOVA, p = 0.6). Furthermore, the presence of IgM 
in the ﬁ  rst week did not correlate with viral load, which 
suggests that virus levels in the ﬁ  rst week can be regarded 
as an independent prognostic parameter. Namely, viral load 
seemed to be strongly related to the clinical classiﬁ  cation 
(p<0.001), with the average log value 9.25 (1.78 × 109) in 
the group of patients who died and 6.91 (8.06 × 106) in the 
group who survived (Figure).
To determine whether IgG could inﬂ  uence viremia, 
viral loads were correlated with log-transformed recipro-
cal antibody titers. Quantitative IgG levels showed a highly 
signiﬁ  cant inverse correlation with viral loads (p<0.0001) 
(Figure). It was thus reasoned that IgG levels could inﬂ  u-
ence the later course of disease and, in particular, could re-
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Table. Detection of CCHF viral load by real-time RT-PCR in serum of patients with acute CCHF, Kosovo* 
Patient no.  Disease severity  Day of illness  IgM titer  IgG titer  Viral load (copies/mL) 
1 Fatal 2 Neg Neg 6.5100 × 10
8
2 Fatal 3 Neg Neg 2.5040 × 10
9
3 Fatal 4 Neg Neg 2.7400 × 10
9
4 Fatal 9 Neg Neg 3.3840 × 10
9
5 Fatal 4 1,600 Neg 1.0160 × 10
8
6 Fatal 6 3,200 Neg 1.3450 × 10
10
7 Fatal 7 400 Neg 1.8675 × 10
9
8 Fatal 7 800 Neg 3.4800 × 10
9
9 Fatal 7 800 Neg 1.2920 × 10
9
8 >6,400 Neg 1.6050 × 10
6 10 Severe
18 >6,400 400 1.1500 × 10
5
9 Neg Neg 2.3250 × 10
7 11 Severe
24 >6,400 >6,400 Neg
4 800 Neg 3.3900 × 10
6 12 Severe
16 6,400 3,200 Neg
2 Neg Neg 1.0430 × 10
9
9 >6,400 400 3.1200 × 10
3
13 Severe
42 >6,400 3,200 Neg
8 Neg Neg 8.1000 × 10
6 14 Severe
14 6,400 Neg 2.0100 × 10
3
3 Neg Neg 3.8100 × 10
7 15 Severe
14 6,400 200 Neg
3 >1,600 Neg 2.5235 × 10
6 16 Severe
6 >800 >800 2.2350 × 10
4
4 Neg Neg 3.3600 × 10
7 17 Severe
10 >6,400 100 3.8100 × 10
4
2 Neg Neg 7.8500 × 10
7
9 6,400 400 3.2000 × 10
3
18 Severe
23 >6,400 >6,400 Neg
12 >6,400 Neg 5.7525 × 10
4 19 Moderate
17 >6,400 800 Neg
9 >6,400 1,600 1.9600 × 10
3 20 Moderate
11 >6,400 3,200 Neg
12 >6,400 800 1.9191 × 10
5
13 >6,400 3,200 1.0240 × 10
4
21 Moderate
32 >6,400 >6,400 Neg
10 >6,400 Neg 4.6400 × 10
4
19 >6,400 >6,400 1.2000 × 10
3
22 Moderate
26 >6,400 >6,400 Neg
9 6,400 6,400 7.6800 × 10
3 23 Moderate
20 >6,400 >6,400 7.5000 × 10
2
7 400 Neg 7.4400 × 10
5 24 Moderate
18 >6,400 6,400 Neg
*CCHF, Crimean-Congo hemorrhagic fever: RT-PCR, reverse transcription–PCR; Ig, immunoglobulin; neg, negative result. Viral Load as Predictor of CCHF Outcome 
ﬂ  ect a discrimination between severe and moderate cases. 
In samples from both categories, no relationship between 
IgG and clinical classiﬁ  cation (p = 0.65) was determined 
after day 7. Also, no signiﬁ  cant relationship was found 
between clinical classiﬁ  cation and viral load (p = 0.74) in 
severe versus moderate cases. On average, viral load log 
value was 2.38 in severe cases and 2.69 in moderate cases 
(Figure).
Conclusions
This study describes the differential inﬂ  uences  of 
CCHF viral load, IgM, IgG, and clinical outcome. CCHF 
viral load, but not IgM, could be used as a predictor of 
CCHF outcome. It was unexpected that IgM correlated 
with neither outcome nor viral load. On the contrary, quan-
titative IgG levels inversely correlated with viral loads, 
which suggests that IgG might neutralize virus in vivo. The 
fact that virus titers decreased in survivors independent of 
antibodies during the ﬁ  rst week implies involvement of in-
nate or cellular immune mechanisms in the elimination of 
CCHF virus.
CCHF viral load ranged from 102 to 1010 copies/mL 
in the serum samples. It was shown that viral load of >108 
copies/mL is a strong factor (p<0.001) for differentiating 
CCHF patients who died from those who survived. Howev-
er, viral load does not help differentiate between severe and 
moderate cases according to common case deﬁ  nitions (4). 
The same was true for IgM levels. Viral load is also useful 
for estimating need for infection control measures. Viral 
loads measured in our patients were high, >109 copies/mL, 
higher than viral loads in other arboviral diseases that are 
not easily transmitted in the hospital, e.g., dengue (12). 
This ﬁ  nding could help explain why CCHF virus causes 
nosocomial infections on a regular basis. Another use for 
this ﬁ  nding is systematic monitoring of patients receiving 
ribavirin therapy. In the absence of sufﬁ  ciently large num-
bers of treated patients, however, we could not investigate 
this application.
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Figure. Correlation between clinical outcome, serologic data, and Crimean-Congo hemorrhagic fever (CCHF) viral load measurements. 
A) Viral load versus immunoglobulin (Ig) M result taken during the ﬁ  rst week of illness. B) Viral load versus outcome. Average viral loads 
were 1.6 × 109 copies/mL in persons who died and 5 × 106 copies/mL in persons who survived (difference highly signiﬁ  cant, p<0.0001). 
The dot is a datum point that has been identiﬁ  ed as an outlier. C) Statistically signiﬁ  cant difference (p<0.001) in CCHF viral load and day 
of illness between group who died and group who survived. D) No correlation in viral load and day of illness between severe and moderate 
CCHF cases. E) Inverse correlation of quantitative IgG levels with viral loads (p<0.0001) in samples taken after ﬁ  rst week of illness. Black 
dot, >1 sample; *, ﬁ  rst week samples. DISPATCHES
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